FDA Eases Biosimilar Rules, Saves $20M in Costs
FDA’s 4th draft guidance revision streamlines biosimilar PK testing, allowing non-U.S. comparators with analytical justification to cut $20M costs and speed approvals.
Category: FDA Compliance
76% Healthcare AI Pilots Stall on Regs
Explore why 76% of healthcare AI pilots stall due to regulatory gaps in HIPAA, EU AI Act, FDA rules. Learn compliance strategies and governance best practices for safe scaling.
FDA Top Regulator Exit Hits Pharma Profits
Explore how Vinay Prasad’s resignation from FDA’s CBER amid regulatory clashes disrupts pharma profits, rare disease approvals, and vaccine strategies. Analyze impacts, compliance shifts, and future enforcement.
FDA QMSR 2026: Implementation guide for manufacturers
Learn new requirements of FDA QMSR implementation: How to align with ISO 13485, bridge gaps in records/labeling, prepare for risk-based inspections, and avoid shutdown risks.
Cassidy Slams FDA Black Box: Pharma Delays Cost Billions
Explore Sen. Cassidy’s critique of FDA’s black box delays costing pharma billions. Learn reforms, impacts, compliance tips for drug approvals and regulatory uncertainty
Virtual Supervision is oked by CMS: Significant Changes to Medicare Physician Supervision Rules
Learn CMS permanent virtual direct supervision rules for Medicare Part B services, effective 2026. Understand compliance, operational impacts, and revenue opportunities.
State law changes on processed foods – 2025
Learn 2025 state laws in Texas SB 25 and Louisiana SB 14 mandating warning labels/QR codes for 44 food additives, school bans, and compliance steps for manufacturers.
FDA Eliminates Biosimilar Testing Requirements, Slashing Development Costs
Understand FDA’s Oct. 2025 biosimilar framework that eliminates efficacy studies and cuts $100M+ costs via analytics, streamlines interchangeability for faster market entry.
FDA Warning Crushes ExThera Blood Filter Sales
Understand FDA’s warning letter to ExThera over Seraph 100 blood filter violations: unapproved marketing claims, compassionate use failures, and compliance steps for device makers.
FDA Speeds Rare Disease Approvals: Biotech Boom Ahead
Understand FDA’s Plausible Mechanism Framework: draft guidance enables single-trial approvals for ultra-rare genetic therapies using mechanistic evidence, natural history data, and post-approval monitoring.